- Home
- LGI vs KPTI Comparison
LGI vs KPTI Comparison
Compare LGI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | KPTI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.6M | 194.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | LGI | KPTI |
|---|---|---|
| Price | $18.06 | $9.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 32.3K | ★ 339.8K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $15.32 | $3.65 |
| 52 Week High | $19.88 | $10.99 |
Technical Indicators
Market Signals| Indicator | LGI | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 51.28 |
| Support Level | $17.29 | $5.40 |
| Resistance Level | $18.37 | $9.45 |
| Average True Range (ATR) | 0.30 | 0.73 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 74.49 | 32.96 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).